Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) dropped 2.8% during trading on Tuesday . The stock traded as low as $13.15 and last traded at $14.45. Approximately 978,000 shares were traded during mid-day trading, a decline of 13% from the average daily volume of 1,125,797 shares. The stock had previously closed at $14.05.
Several brokerages have recently issued reports on AMAG. Cantor Fitzgerald restated a “hold” rating and set a $21.00 target price on shares of AMAG Pharmaceuticals in a research report on Thursday, September 28th. Cowen and Company reiterated a “hold” rating on shares of AMAG Pharmaceuticals in a report on Thursday, August 10th. Zacks Investment Research downgraded shares of AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, October 17th. Janney Montgomery Scott restated a “hold” rating on shares of AMAG Pharmaceuticals in a research note on Tuesday, October 17th. Finally, Morgan Stanley dropped their price objective on shares of AMAG Pharmaceuticals from $26.00 to $22.00 and set an “overweight” rating on the stock in a research note on Friday, November 3rd. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $24.00.
The company has a current ratio of 1.59, a quick ratio of 1.48 and a debt-to-equity ratio of 0.94.
Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. grew its position in shares of AMAG Pharmaceuticals by 67,790.9% during the first quarter. BlackRock Inc. now owns 4,995,412 shares of the specialty pharmaceutical company’s stock worth $112,647,000 after buying an additional 4,988,054 shares in the last quarter. Vanguard Group Inc. boosted its holdings in AMAG Pharmaceuticals by 6.1% in the first quarter. Vanguard Group Inc. now owns 3,085,348 shares of the specialty pharmaceutical company’s stock worth $69,576,000 after purchasing an additional 176,832 shares during the period. State Street Corp boosted its holdings in AMAG Pharmaceuticals by 10.6% in the second quarter. State Street Corp now owns 2,789,932 shares of the specialty pharmaceutical company’s stock worth $51,336,000 after purchasing an additional 267,873 shares during the period. Dimensional Fund Advisors LP boosted its holdings in AMAG Pharmaceuticals by 18.5% in the second quarter. Dimensional Fund Advisors LP now owns 1,215,249 shares of the specialty pharmaceutical company’s stock worth $22,361,000 after purchasing an additional 189,576 shares during the period. Finally, Gotham Asset Management LLC boosted its holdings in AMAG Pharmaceuticals by 17.8% in the second quarter. Gotham Asset Management LLC now owns 800,055 shares of the specialty pharmaceutical company’s stock worth $14,721,000 after purchasing an additional 121,137 shares during the period.
TRADEMARK VIOLATION NOTICE: This piece was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece on another site, it was illegally stolen and reposted in violation of U.S. and international copyright law. The legal version of this piece can be read at https://www.chaffeybreeze.com/2017/11/14/amag-pharmaceuticals-inc-amag-trading-down-2-8.html.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.